| __timestamp | Apellis Pharmaceuticals, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 381287000 |
| Thursday, January 1, 2015 | 6356782 | 452612000 |
| Friday, January 1, 2016 | 4303743 | 316800000 |
| Sunday, January 1, 2017 | 10463151 | 330100000 |
| Monday, January 1, 2018 | 22639184 | 265800000 |
| Tuesday, January 1, 2019 | 67046483 | 336200000 |
| Wednesday, January 1, 2020 | 139401000 | 423900000 |
| Friday, January 1, 2021 | 176771000 | 467000000 |
| Saturday, January 1, 2022 | 277163000 | 487000000 |
| Sunday, January 1, 2023 | 500815000 | 477100000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. United Therapeutics Corporation and Apellis Pharmaceuticals, Inc. offer a fascinating contrast in their SG&A spending from 2014 to 2023.
United Therapeutics consistently maintained higher SG&A expenses, peaking at approximately $487 million in 2022, reflecting a strategic focus on robust administrative and sales operations. In contrast, Apellis Pharmaceuticals, starting with a modest $2.9 million in 2014, saw a dramatic increase, reaching around $501 million by 2023. This represents a staggering growth of over 17,000%, highlighting Apellis's aggressive expansion and investment in administrative capabilities.
This decade-long analysis underscores the dynamic strategies of these biotech giants, offering insights into their operational priorities and market positioning.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights